AGN Stock Recent News Allergan Inc (AGN) 196.00 11/09/2014 1

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 1:43 PM

Allergan Inc (AGN) 196.00 $AGN

Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.00 (-1.40), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), NVS: 91.76 (-0.27)

Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)

Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 196.00 (-1.40), HCA: 65.75 (-3.22), BIDU: 236.54 (-0.36), ZBRA: 72.59 (-1.29), SWKS: 59.88 (-2.26), ALK: 55.14 (-0.26), CELG: 106.45 (-0.69)

AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), AZN: 72.88 (+0.03), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40)

These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), HHC: 149.47 (-0.85), PAH: 25.79 (+0.11), CP: 206.47 (+0.78), APD: 134.94 (-0.07), BKW: 32.60 (-0.72)

Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), AUXL: 32.75 (-0.52), SLXP: 91.47 (-47.08)

Cramer: Salix Pharmaceuticals' Audit Committee Review Is Concerning
at The Street - Fri Nov 07, 9:54AM CST
TheStreet's Jim Cramer takes a look at Salix Pharmaceuticals, whose stock is plunging after the company announced a slew of bad news.
AGN: 196.00 (-1.40), SLXP: 91.47 (-47.08)

SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), SRDX: 20.44 (-0.56), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21)

Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan
Thomson Reuters ONE - Fri Nov 07, 2:20AM CST
Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan . Ad hoc announcement according to 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AGN: 196.00 (-1.40)

Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 196.00 (-1.40), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21), HSP: 56.32 (-0.32)

Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), MSFT: 48.68 (-0.02), VZ: 50.86 (+0.58)

Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), PRGO: 155.77 (+3.28), ABBV: 61.50 (-1.21)

Uptrend Call Working As Allergan Stock Rises 18.8% (AGN)
Comtex SmarTrend(R) - Thu Nov 06, 9:59AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 18.85% as of today's recent price of $198.60.
AGN: 196.00 (-1.40)

Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 196.00 (-1.40), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), ABBV: 61.50 (-1.21)

How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21)

Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), SWKS: 59.88 (-2.26), AKRX: 36.59 (-1.29), SLXP: 91.47 (-47.08), AAPL: 109.01 (+0.31)

Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47)

New Survey Shows Nearly 60% Of Women Say They Would Rather Have A More Youthful Looking Face Than A More Youthful Looking Body(1)
PR Newswire - Wed Nov 05, 3:25PM CST
According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
AGN: 196.00 (-1.40)

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 196.00 (-1.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Coastal Construction Revamps South Florida's Equipment Game

Revolutionizing Equipment Acquisition in South Florida Looks like the sun's shining a bit differently on South Florida's contractors. Coastal Construction Equipment, LLC just announced their big debut as a new player on the Cat Compact™ scene, turning the tides for those in the construction industry. With a plan that's as big as a bulldozer, they'll be breaking ground,...

NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Villas of Distinction Shines: Bags 11th Gold Travvy

Claiming Top Spot Repeatedly Another year, another accolade—Villas of Distinction has clutched its 11th Gold Travvy Award for "Best Villa Rental Company – Overall." This accolade ain't no small potatoes, as it's a testament to the company's unwavering excellence recognized by travel advisors worldwide. These folks, who have their fingers on the pulse of the industry,...

Silver Oak Sells CCS, Setting Stage for Further Growth

Wind Point Partners Acquires CCS: A Strategic Shift All right, let's cut to the chase: Silver Oak just offloaded CCS Facility Services to Wind Point Partners. We're talking about a private equity giant making moves in the janitorial sector. If you find this snoozy, think again. This ain't just about swapping keys of a janitorial firm. It's about money moves and strategic...

GOFO: Transformative Shifts in U.S. Parcel Dynamics

Once upon a time, the last-mile delivery game in the U.S. was the backyard brawl of a few heavy hitters—USPS, UPS, and FedEx slugging it out for package supremacy. But fast-forward to today's parcel market, and things are looking more like a chaotic street party with Amazon now leading the dance. The scene's thinning in some corners while swelling in others. Let's pull...

International Tower Hill's Q3 Results: Gold Updates

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....

PCB Technologies Hits Record Q3 Sales: $62M in Orders

PCB Technologies' Stellar Q3: More Than Just Numbers PCB Technologies isn't just riding the wave; it's practically surfing on a tsunami with its latest Q3 financial results. A mix of hard-hitting figures showcases not just growth, but a strategic leap that investors should really be paying attention to. It's about time we peel back the layers and understand what these...

Millrose Properties Faces Class Action Deadline Amid Turmoil

Millrose Properties: Legal Storm Brewing If you've got stock in Millrose Properties, Inc. (NYSE:MRP), you might want to listen up. There's a class action lawsuit in the works that could have quite the impact. Investors have until December 8, 2026, to throw their hat in the ring and maybe even lead the charge on this lawsuit. The Allegations Up Close Let's break down what...

Iconic Brands Falter in New AI-Driven Consumer Landscape

Forget Recognition—It's All About Relevance Now Brand hearts are breaking, folks. That classic suite of household names just took a body blow from the Consequential Brand™ Test. Out of 73, a single champ emerged. Why? Because in the age where AI drives recommendations, it turns out recognizability ain't cutting it. This ain't your granddad’s customer loyalty game...